Amgen, Inc. is moving its closely watched KRAS inhibitor sotorasib (AMG 510) forward at an aggressive pace with plans to seek accelerated approval based on a single-arm Phase II monotherapy trial in non-small cell lung cancer (NSCLC) if the results are consistent with new Phase I data published in the New England Journal of Medicine and presented at the European Society of Medical Oncology (ESMO) Virtual Congress.
The NEJM publication and ESMO presentation on 20 September showed a confirmed overall response (ORR) rate of 35.3% (all partial...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?